证券代码： 301097 证券简称：天益医疗 公告编号：2025-048 宁波天益医疗器械股份有限公司 关于公司股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）于近日接到公司实际 控制人、持股5%以上股东吴斌先生的通知，其将所持本公司股份办理了解除质押 及质押业务，具体事项如下： 一、股东股份质押的基本情况 | | 是否为控股 | 本次解除 | 占其 | 占公 | | 是否 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | 质押数量 | 所持 | 司总 | 是否为限 | 为补 | 质押起 | 质押到 | 质权人 | | 名称 | 大股东及其 | （股） | 股份 | 股本 | 售股 | 充质 | 始日 | 期日 | | | | 一致行动人 | | 比例 | 比例 | | 押 | | | | | 吴斌 | 是 | 4,500,000 | 37.50 | 7.63 ...

责任编辑：小浪快报 截至6月30日，天益医疗股东户数4196.00，较上期减少0.31%；人均流通股4372股，较上期增加0.31%。 2025年1月-6月，天益医疗实现营业收入2.27亿元，同比增长11.50%；归母净利润948.32万元，同比减少 35.23%。 分红方面，天益医疗A股上市后累计派现1.02亿元。近三年，累计派现8749.78万元。 机构持仓方面，截止2025年6月30日，天益医疗十大流通股东中，鹏华弘嘉混合A（003165）位居第四 大流通股东，持股49.87万股，持股数量较上期不变。圆信永丰聚优A（010469）位居第八大流通股东， 持股28.70万股，相比上期减少2.80万股。圆信永丰医药健康A（006274）位居第十大流通股东，持股 23.00万股，相比上期减少4.55万股。鹏华优质治理混合(LOF)A（160611）退出十大流通股东之列。 9月8日，天益医疗盘中上涨2.08%，截至09:48，报45.14元/股，成交393.43万元，换手率0.48%，总市值 26.61亿元。 天益医疗今年以来股价涨25.00%，近5个交易日涨2.13%，近20日跌4.73%，近60日涨15.71 ...

证券代码：301097 证券简称：天益医疗 公告编号：2025-047 宁波天益医疗器械股份有限公司 一、对外投资概述 宁波天益医疗器械股份有限公司（以下简称"公司"或"天益医疗"）于 2025 年 2 月 14 日召开第三届董事会第二十一次会议，审议通过了《关于对外投 资的议案》，同意通过新加坡全资子公司 PRIMACRON GLOBAL PTE. LTD.（潽莱 马克隆国际有限公司，以下简称"潽莱马克隆"或"买方"）向 BELLCO S.R.L. （以下简称"卖方"）收购其 CRRT-滤器业务资产（以下简称"标的业务"）。 具体内容详见公司于 2025 年 2 月 15 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于对外投资的公告》（公告编号：2025-008）。 二、对外投资进展情况 截至本公告披露日，子公司潽莱马克隆与卖方已完成标的业务的交割工作， 卖方已将标的资产注入其为本次收购之目的于 2025 年 2 月 28 日登记设立的全资 子公司 PRIMABELL S.R.L.（意大利潽莱马贝而有限公司），并已将意大利潽莱 马贝而有限公司的 100%的股份转让给潽莱马克隆。现将相关情 ...

证券代码：301097 证券简称：天益医疗 公告编号：2025-046 宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 并签署募集资金四方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"或"公司"）于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》，同意变更募集资金用途，同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目"，并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目"；同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日，公司已完成在上海浦东发展银行宁波高新区支行募集资 金专项账户的开立及募集资金四方监管协议的签署，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开发 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has announced the cancellation of medical device registration certificates for two products from two companies, indicating regulatory actions in the medical device industry [1] Company Summaries - Shenzhen Huada Yinyuan Medical Technology Co., Ltd. had its registration certificate for an automatic medical PCR analyzer (Registration No. 20233221432) revoked [1] - Ningbo Tianyi Medical Instruments Co., Ltd. had its registration certificate for a disposable titration infusion device with needle (Registration No. 20163141122) revoked [1]

Group 1 - Tianyi Medical (301097) announced that the company and its wholly-owned subsidiaries and joint ventures have not provided guarantees to any off-balance sheet entities [1] - There are no overdue external guarantees, no guarantees involved in litigation, and no losses incurred due to guarantees resulting in adverse judgments [1]

Group 1 - The company Tianyi Medical announced that as of the disclosure date, the total guarantee amount provided to its subsidiaries is approximately 489 million RMB, accounting for 41.03% of the company's latest audited consolidated net assets [1] - The actual total guarantee balance provided by the company to its subsidiaries is about 153 million RMB, which represents 12.81% of the company's latest audited consolidated net assets [1] - As of the disclosure date, the total guarantee amount provided by subsidiaries to the company is 190 million RMB, accounting for 15.94% of the company's latest audited consolidated net assets [1] Group 2 - For the first half of 2025, the revenue composition of Tianyi Medical is as follows: medical devices account for 98.81%, while other sources account for 1.19% [2] Group 3 - As of the time of reporting, the market capitalization of Tianyi Medical is 2.6 billion RMB [3]

证券代码：301097 证券简称：天益医疗 公告编号：2025-045 宁波天益医疗器械股份有限公司 关于全资子公司为母公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、因公司经营发展需要，宁波天益医疗器械股份有限公司（以下简称"公 司"或"天益医疗"）拟与上海浦东发展银行股份有限公司宁波分行（以下简称 "浦发银行宁波分行"）签订《借款合同》，全资子公司宁波天益药业科技有限公 司（以下简称"天益药业"）拟与浦发银行宁波分行签订《最高额保证合同》，为 母公司天益医疗提供总金额人民币 1.9 亿元的连带责任保证。 2、本次担保的性质：连带责任保证。 3、本事项无需提交公司董事会及股东会审议，由相关子公司就担保事项履 行内部审批程序。 一、担保情况概述 因公司经营发展需要，天益医疗拟与浦发银行宁波分行签订《借款合同》， 全资子公司天益药业拟与浦发银行宁波分行签订《最高额保证合同》，为母公司 天益医疗提供总金额人民币 1.9 亿元的连带责任保证。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 ...

Summary of Key Points Core Viewpoint - Tianyi Medical's stock experienced a decline of 2.77% on August 28, with a trading volume of 66.35 million yuan, indicating potential market volatility and investor sentiment concerns [1]. Financing and Trading Data - On August 28, Tianyi Medical had a financing purchase amount of 10.72 million yuan and a net financing purchase of 5.96 million yuan, with a total financing and securities balance of 31.14 million yuan, accounting for 3.83% of its market capitalization [1]. - The financing balance is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - There were no short sales or repayments on the same day, with the short selling balance also at zero, placing it in the 90th percentile of the past year [1]. Company Overview - Tianyi Medical, established on March 12, 1998, and listed on April 7, 2022, specializes in the research, production, and sales of medical devices, particularly in blood purification and ward care [1]. - The company's revenue composition includes 59.05% from blood purification, 34.08% from ward care, and 6.87% from other sources [1]. Financial Performance - For the first half of 2025, Tianyi Medical reported a revenue of 227 million yuan, reflecting a year-on-year growth of 11.50%, while the net profit attributable to shareholders decreased by 35.23% to 9.48 million yuan [2]. - The total number of shareholders as of June 30 was 4,196, a slight decrease of 0.31%, with an average of 4,372 circulating shares per person, which increased by 0.31% [2]. Dividend and Shareholder Information - Since its A-share listing, Tianyi Medical has distributed a total of 102 million yuan in dividends, with 87.50 million yuan distributed over the past three years [3]. - As of June 30, 2025, the top ten circulating shareholders included notable funds, with some holdings remaining stable while others saw slight reductions [3].

Core Insights - Tianyi Medical (301097) reported a revenue increase but a decline in net profit for the first half of 2025, with total revenue reaching 227 million yuan, up 11.5% year-on-year, while net profit attributable to shareholders fell by 35.23% to 9.48 million yuan [1] - The company's gross margin decreased to 35.48%, down 4.42% year-on-year, and net margin dropped to 4.53%, down 30.0% [1] Financial Performance - For Q2 2025, total revenue was 129 million yuan, reflecting a year-on-year increase of 20.43, while net profit attributable to shareholders was 4.61 million yuan, a significant decline of 50.11% [1] - Total expenses (selling, administrative, and financial) amounted to 46.09 million yuan, accounting for 20.27% of revenue, which is an increase of 6.95% year-on-year [1] - Earnings per share decreased by 46.67% to 0.16 yuan, while operating cash flow per share increased by 17.8% to 0.54 yuan [1] Business Evaluation - The company's historical median Return on Invested Capital (ROIC) stands at 18.18%, but the worst year recorded a ROIC of -0.78% in 2024, indicating poor investment returns [2] - The company has experienced one loss year since its listing, necessitating further investigation into potential special circumstances [2] Debt and Cash Flow - The company maintains a healthy cash asset position, but the interest-bearing debt ratio has reached 25.75%, warranting attention to its debt situation [2] - The business model relies heavily on capital expenditures, which raises concerns about the viability and necessity of these investments [2]